Exploring Monoclonal Antibodies for Migraine Prevention

This chapter examines a phase two trial assessing a monoclonal antibody treatment for migraine prevention, highlighting its effectiveness in reducing migraine days and evaluating safety. It discusses the study's limitations and the ongoing debates regarding the interactions between the central and peripheral systems in migraine pathophysiology.